48L Stock Overview
Operates as a commercial-stage medical device and biopharmaceutical company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Beyond Air, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.88 |
| 52 Week High | US$4.40 |
| 52 Week Low | US$0.88 |
| Beta | 0.013 |
| 11 Month Change | -12.00% |
| 3 Month Change | -44.44% |
| 1 Year Change | -79.99% |
| 33 Year Change | -84.12% |
| 5 Year Change | n/a |
| Change since IPO | -82.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 48L | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -22.8% | 1.6% | 0.9% |
| 1Y | -80.0% | 0.3% | 4.2% |
Return vs Industry: 48L underperformed the German Medical Equipment industry which returned 0.3% over the past year.
Return vs Market: 48L underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| 48L volatility | |
|---|---|
| 48L Average Weekly Movement | 12.6% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 48L's share price has been volatile over the past 3 months.
Volatility Over Time: 48L's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 107 | Steve Lisi | www.beyondair.net |
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.
Beyond Air, Inc. Fundamentals Summary
| 48L fundamental statistics | |
|---|---|
| Market cap | €27.81m |
| Earnings (TTM) | -€56.21m |
| Revenue (TTM) | €1.08m |
25.7x
P/S Ratio-0.5x
P/E RatioIs 48L overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 48L income statement (TTM) | |
|---|---|
| Revenue | US$1.16m |
| Cost of Revenue | US$2.47m |
| Gross Profit | -US$1.31m |
| Other Expenses | US$58.94m |
| Earnings | -US$60.24m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.31 |
| Gross Margin | -112.77% |
| Net Profit Margin | -5,197.76% |
| Debt/Equity Ratio | 57.1% |
How did 48L perform over the long term?
See historical performance and comparison